NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis $2.15 +0.06 (+2.92%) As of 09:37 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Seres Therapeutics Stock (NASDAQ:MCRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seres Therapeutics alerts:Sign Up Key Stats Today's Range$2.01▼$2.2050-Day Range$1.77▼$5.7252-Week Range$1.67▼$29.98Volume94,587 shsAverage Volume76,404 shsMarket Capitalization$21.62 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Seres Therapeutics, Inc. is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption. Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment. VOWST is an orally administered microbiome-based therapy and was among the first products of its kind to receive FDA approval. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Seres has historically developed additional microbiome-based candidates for gastrointestinal and other immune-related conditions through clinical programs and collaborations. VOWST has been commercialized in the United States, while the company’s research and development activities have supported broader efforts to develop microbiome therapeutics for patients with serious diseases.AI Generated. May Contain Errors. Read More Seres Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreMCRB MarketRank™: 2.937440886365 of 5 starsSeres Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 345th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingSeres Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSeres Therapeutics has a consensus price target of $17.00, representing about 713.4% upside from its current price of $2.09.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Seres Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($6.33) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.28% of the float of Seres Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 3.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seres Therapeutics has recently decreased by 0.61%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.34 News SentimentSeres Therapeutics has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Seres Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,230.00 in company stock.Percentage Held by Insiders5.20% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seres Therapeutics' insider trading history. Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MCRB Stock News HeadlinesSeres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related ...November 4 at 9:07 AM | markets.businessinsider.comSeres Therapeutics: Q3 earnings snapshotNovember 4 at 9:07 AM | msn.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Efficiency under President Trump - has gone on record saying the U.S. is '1,000% going to go bankrupt' if the trajectory doesn't change. The Trump administration preserved a little-known IRS loophole that allows everyday Americans to shield their retirement savings from the next wave of market turbulence. A free 2026 Wealth Protection Guide walks through the steps to use it.November 6 at 1:00 AM | American Hartford Gold (Ad)Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...November 3 at 8:01 AM | markets.businessinsider.comSeres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation RecipientsNovember 3 at 7:00 AM | globenewswire.comSeres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients ...October 15, 2026 | markets.businessinsider.comSeres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026October 15, 2026 | globenewswire.comSeres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMSee More Headlines MCRB Stock Analysis - Frequently Asked Questions How have MCRB shares performed this year? Seres Therapeutics' stock was trading at $14.88 at the start of the year. Since then, MCRB stock has decreased by 86.0% and is now trading at $2.09. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings results on Wednesday, November, 4th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.00) by $0.63. The biotechnology company earned $593 thousand during the quarter, compared to analysts' expectations of $6.35 million. Seres Therapeutics had a negative net margin of 2,209.55% and a negative trailing twelve-month return on equity of 175.40%. When did Seres Therapeutics' stock split? Seres Therapeutics shares reverse split on the morning of Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $119 million in an initial public offering on Friday, June 26th 2015. The company issued 7,430,555 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include NVIDIA (NVDA), PayPal (PYPL), Micron Technology (MU), Alibaba Group (BABA), Pfizer (PFE), NIO (NIO) and Workhorse Group (WKHS). Company Calendar Last Earnings11/04/2026Today11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MCRB's financial health is in the Red zone, according to TradeSmith. MCRB has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MCRB CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees66Year Founded2010Price Target and Rating Average Price Target for Seres Therapeutics$17.00 High Price Target$22.00 Low Price Target$12.00 Potential Upside/Downside+713.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.70 million Net Margins-2,209.55% Pretax Margin-1,192.94% Return on Equity-175.40% Return on Assets-51.65% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$790 thousand Price / Sales26.59 Cash Flow$1.09 per share Price / Cash Flow1.92 Book Value$4.89 per share Price / Book0.43Miscellaneous Outstanding Shares10,050,000Free Float9,523,000Market Cap$21.00 million OptionableOptionable Beta0.44 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MCRB) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredTrump compared today's market to 1929, not once but twicePresident Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredCritical SpaceX supplier w/ patented tech trading for $5President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredOne stock to sell now that Libs have taken overA veteran analyst dubbed The Prophet by CNBC believes a major shift in Washington could create a rare opportun...Stansberry Research | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
